Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Common Equity (2017 - 2025)

Cue Biopharma's Common Equity history spans 9 years, with the latest figure at $13.2 million for Q3 2025.

  • For Q3 2025, Common Equity fell 47.78% year-over-year to $13.2 million; the TTM value through Sep 2025 reached $13.2 million, down 47.78%, while the annual FY2024 figure was $17.5 million, 52.81% down from the prior year.
  • Common Equity for Q3 2025 was $13.2 million at Cue Biopharma, down from $18.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $72.9 million in Q2 2021 and bottomed at $6.6 million in Q1 2025.
  • The 5-year median for Common Equity is $46.0 million (2023), against an average of $43.5 million.
  • The largest annual shift saw Common Equity surged 54.01% in 2021 before it tumbled 78.09% in 2025.
  • A 5-year view of Common Equity shows it stood at $65.5 million in 2021, then increased by 0.29% to $65.7 million in 2022, then tumbled by 43.54% to $37.1 million in 2023, then plummeted by 52.81% to $17.5 million in 2024, then dropped by 24.3% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Common Equity are $13.2 million (Q3 2025), $18.2 million (Q2 2025), and $6.6 million (Q1 2025).